Description: Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden.
Home Page: www.lipigon.se
TvistevAegen 48 C
Umeå,
90736
Sweden
Phone:
46 7 05 78 17 68
Officers
| Name | Title |
|---|---|
| Mr. Lars Öhman | Business Development Manager & Chairman |
| Dr. Stefan K. Nilsson | Co-Founder & CEO |
| Mr. Hugo Petit | Chief Financial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8029 |
| Price-to-Sales TTM: | 0.2344 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |